Evaluating an Investigational Intravenous Treatment for Recent-Onset CRPS-1
Neurovations Research in Napa, California is currently enrolling eligible adults in the CRPS-RISE Phase 3 Clinical Trial. If you or a loved one were recently diagnosed with CRPS-1 in an arm, leg, hand, or foot, you may qualify to participate in clinical research right here in Northern California.
- No Cost to Participate: Trial-related study procedures, medication, and care are provided at no cost.
- Local Expert Care: Supervised by Principal Investigator Dr. Eric Grigsby and the Neurovations clinical team.
About the Study
Advancing Research for CRPS Relief
The CRPS-RISE Study is a pivotal Phase 3, triple-blind, placebo-controlled clinical research trial sponsored by Ambros Therapeutics. The trial is evaluating an investigational medicine called Neridronate for adults living with Complex Regional Pain Syndrome Type 1 (CRPS-1).
How the Trial Works
-
Investigational Medication: Participants are randomly assigned (by chance) to receive either the investigational medication (Neridronate) or a placebo (an inactive liquid that looks identical).
-
Treatment Delivery: Administered via four intravenous (IV) infusion visits during the first two weeks.
-
Goal of Research: To evaluate whether Neridronate can help reduce persistent pain and symptoms associated with CRPS-1.
Is this Study for me?
To be considered for participation at our Napa research center, candidates must meet the following primary criteria.
Age
18 years of age or older
Onset Timeline
CRPS symptoms developed within the last 6 months
CRPS Subtype
Diagnosed with or exhibiting symptoms of the "Warm Subtype" of CRPS-1 (the affected limb displays redness, warmth, or swelling)
Location
Able to travel to the Neurovations Research center in Napa, CA for scheduled infusion visits and health evaluations
See If you Qualify
Complete the secure form below or call us at 707-252-9606. Our team will contact you within 48 hours.
Study Participation and Your Safety
Participant safety is our number one priority during every stage of the study process. All research studies are carefully supervised, monitored, and documented. Every research study is reviewed and approved by a special group of people called an Institutional Review Board (IRB) or an Ethics Committee (EC), which is made up of scientists, nonscientist professionals, and members of the public. They make sure that participants’ rights are protected, and they seek to avoid exposure to unnecessary risks. IRBs and ECs will only approve studies that they think could help
answer important medical questions.
While the research study is ongoing, a team of study doctors and nurses at the study site will closely monitor your health. If you have questions or concerns at any point throughout the study, a study staff member is available.
Your participation is voluntary, and you are free to withdraw at any time for any reason. Although others can help make up your mind, the final decision is yours to make. Your privacy will be maintained throughout the study.
About Neurovations Research
Neurovations Research, founded in 2010, is at the forefront of innovation in the field of pain and neuromodulation. CEO and founder Dr. Eric Grigsby has led clinical trials with more than fifty companies, partnering with industry leaders and early-stage companies in medical device (Phase I-IV) and pharmaceutical trials (Phase II-IV), including first-in-man medical device trials, double-blinded and placebo-controlled trials.